Cancer Immunol Res. 2026 Jan 12:OF1-OF8. doi: 10.1158/2326-6066.CIR-25-1479. Online ahead of print. ABSTRACT The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving … Read more
Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873. Online ahead of print. ABSTRACT Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. Here, we show that urinary tract infections (UTI) caused by P. aeruginosa exacerbated … Read more
Cancer Immunol Res. 2026 Jan 9:OF1-OF11. doi: 10.1158/2326-6066.CIR-25-1018. Online ahead of print. ABSTRACT The gut microbiome has emerged as a modulator of both cancer progression and patient responses to therapies like immune checkpoint inhibitors (ICI). Recent evidence highlights microbially derived metabolites as key regulators of immune response and tumor microenvironment dynamics. This review explores the … Read more
Cancer Immunol Res. 2026 Jan 8. doi: 10.1158/2326-6066.CIR-25-0880. Online ahead of print. ABSTRACT The ability of interleukin-12 (IL-12) to stimulate production of interferon gamma (IFN-γ) suggested it might improve the efficacy of low dose interferon alpha (IFN-α). In this phase II trial, patients with metastatic malignant melanoma were administered recombinant human (rh) IL-12 followed by … Read more
Cancer Immunol Res. 2026 Jan 8;14(1):7. doi: 10.1158/2326-6066.CIR-14-1-WWR. NO ABSTRACT PMID:41502309 | DOI:10.1158/2326-6066.CIR-14-1-WWR
Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. NO ABSTRACT PMID:41502310 | DOI:10.1158/2326-6066.CIR-25-1391
Cancer Immunol Res. 2026 Jan 7. doi: 10.1158/2326-6066.CIR-25-0834. Online ahead of print. ABSTRACT While the role of neutrophils in modulating antitumor T cell responses has been extensively studied, their direct effects on tumor cells remains less well understood. In this study, we investigated whether neutrophils have the capacity to directly kill tumor cells independently of … Read more
Cancer Immunol Res. 2025 Dec 29. doi: 10.1158/2326-6066.CIR-25-0583. Online ahead of print. ABSTRACT Relapsed and refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer … Read more
Cancer Immunol Res. 2025 Dec 9. doi: 10.1158/2326-6066.CIR-25-0242. Online ahead of print. ABSTRACT Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. Here, we demonstrated that anti-PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine interferon IFN-γ. Mechanistically, IFN-γ-induced … Read more
Cancer Immunol Res. 2025 Dec 8. doi: 10.1158/2326-6066.CIR-25-0070. Online ahead of print. ABSTRACT Vaccines that encode tumour-associated antigens are potent boosting agents for adoptively transferred tumour-specific T cells. Employing vaccines to boost adoptively transferred tumour-reactive T cells relies on a priori knowledge of tumour epitopes, isolation of matched epitope-specific T cells, and personalized vaccines, all … Read more
